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Summary 
Abnormal humoral responses toward motor end plate constituents in muscle induce myasthenia 
gravis  (MG).  To study the etiology of this disease,  and whether it could be induced by host 
defense molecules, we examined the consequences of interferon (IFN) "y production within the 
neuromuscular junction of transgenic mice. The transgenic mice exhibited gradually increasing 
muscular weakness, flaccid paralysis,  and functional disruption  of the neuromuscular junction 
that was reversed after administration  of an inhibitor of acetylcholinesterase, features which are 
strikingly similar to human MG. Furthermore,  histological examination revealed infiltration of 
mononuclear cells and autoantibody deposition at motor end plates. Immunoprecipitation analysis 
indicated that a previously unidentified 87-kD target antigen was recognized by sera from transgenic 
mice and also by sera from the majority of human MG patients studied.  These results suggest 
that expression of IFN-'y at motor end plates provokes an autoimmune humoral response, similar 
to human  MG,  thus linking  the expression of this factor with  development of this disease. 
utoimmune responses to neuromuscular junction com- 
ponents in myasthenia gravis  (MG), 1 such as the nico- 
tinic acetylcholine receptor (nAChR), are largely pathogenic 
humoral responses. Patients suffer from progressive weakness 
of the voluntary muscles and many have autoantibodies against 
the  nAChR,  and  a  similar  experimental  condition,  ex- 
perimental  autoimmune  MG (EAMG),  can be induced by 
the introduction of antibodies to the nAChR (1-3).  Addi- 
tionaUy, autoantibodies that impair neuromuscular transmis- 
sion have been found in some MG patients who lack autoan- 
tibodies to nAChR  (4-7). 
Despite suggestions that viral or bacterial infections may 
trigger human MG, the molecular events leading to the de- 
velopment of the autoimmune response against the neuromus- 
cular junction components remain unknown (8-10). The em- 
phasis  on primary  pathogenic  effects of autoantibodies  is 
relatively uncommon among autoimmune phenomenon with 
the exception of an another neuronal disorder, stiff-man syn- 
drome (11). 
We sought to address the mechanism by which cells  of 
the immune system become sensitized to components in the 
neuromuscular junction.  Our previous studies have focused 
on the effects of cytokines elicited after infection or insult 
and that are capable of stimulating an immune response. While 
the autoimmune response in the neuromuscular junction of 
MG patients  is quite distinct  from  that  observed in other 
autoimmune disorders, we performed studies to determine 
whether molecules produced during the host response to in- 
fection could cause this type of disorder. We chose to study 
the effects of neuromuscular junction expression of the Thl 
lymphokine IFN-% which has a multitude of immunostimula- 
tory properties  (12). 
1 Abbreviations used in  this ~per:  r  c~-bungarotoxin; EAMG, 
experimental autoimmune myasthenia gravis; EM, electron microscopy; 
EMG, electromyogram;  H & E, hematoxylin and eosin; MG, myasthenia 
gravis; nAChR, nicotinic acetylcholine receptor; PSMP, postsynaptic 
membrane protein. 
Materials and Methods 
Production of6-IFN-7-tmnsgenic Mic~  The gene encoding IFN-'y 
was inserted into the BamHI restriction site of the 3.5-kb e gene 
fragment containing the promoter region (13). An 8.8-kb XhoI/SpeI 
fragment containing  the murine e promoter,  the routine  IFN-'y 
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cyte injection  as described previously (14). 
DNA Analysis.  Southern blot analysis of genomic DNA was 
performed.  10 mg of genomic DNA, extracted from 2-cm-long 
tail segments, was digested with AccI enzyme overnight. The DNA 
was electrophoresed  on 0.8% agarose gels and transferred to nitrocel- 
lulose membranes (NitroPure; Micron Separations  Inc., Westboro, 
MA). Hybridization was performed with radiolabeled restriction 
fragments of the IFN-~' cDNA clone (Prime-It  TM random primer 
labeling kit;  Stratagene Inc., La Jolla,  CA). 
In Situ Hybridization.  In situ hybridization confirmed that IFN-y 
was expressed in neuromuscular junctions of e-IFN-3~-transgenic 
mice. Skeletal muscles from 4-mo-old e-IFNq,-transgenic mice were 
placed in Bouin's fixative overnight. Deparaffinized sections were 
prehybridized for 2-3 h at 42~  in a buffer of 50% formamide, 
0.3 M NaC1, 20 mM Tris, pH 8.0, 5 mM EDTA, lx  Denhardt's 
solution, 10% dextran sulfate,  and 10 mM dithiothreitol. Hybrid- 
ization with 3sS-labeled sense and antisense RNA probes (750,000 
cpm/section) was done for 16 h at 42~  in a humidified chamber. 
This was followed by washing, dehydration, and drying. Sections 
were covered with nuclear track emulsion (NTB-2; Eastman Kodak 
Co., Rochester, NY), exposed for 1 wk, and developed. RNA probes 
were prepared by in vitro transcription of linearized plasmid con- 
taining IFN-y cDNA. No significant signals were seen with sense 
probes. 
Antibody Purification.  The isolation and purification of e-trans- 
genic BALB/c mice and human IgG was performed by use of a 
protein A/G  IgG purification  kit  (Pierce Chemical Co.,  Rock- 
ford,  IL). 
Serum Collection.  Sera from MG patients and patients with non- 
myasthenic disorders were supplied by the laboratories of Drs. H. 
Fox and J. Lindstrom with the help of Dr. Marjorie Seybold (The 
Scripps Research Institute). The sera were either stored at 4~  or 
-  70oC. 
Anti-nAChR Antibody Assay.  nAChgs were isolated from the 
mouse cell line BC3H-1 (15). The assay for anti-nAChR antibody 
was performed as follows: 5-#1 aliquots of mouse sera were incubated 
overnight at 4~  with 10 -9 M nAChR labeled with 2  x  10 -9 M 
125I-oeBTX in  100  /zl of PBS  (pH 7.5)  containing  0.5%  Triton 
X-100, and 10 mM NAN3.40/zl of 10% fixed Staphylococcus aureus 
A  (Zysorbin; Zymed Labs,  Inc., South San Francisco,  CA) were 
then added and incubated for 75 rain. After dilution  with  1 ml 
of the same buffer, the S. aureus-antibody-labeled  nAChR precipi- 
tate was pelleted for 5 min in a microfuge. The pellet was washed 
twice, and then the tubes were counted for radioactivity. A blank 
value obtained by using 5 #1 of normal mouse serum in the assay 
was subtracted  from all  measurements.  All  assays were done in 
triplicate. 
Protein Analysis.  Protein analyses  were performed on muscle 
homogenates, crude cell extracts, and purified nAChR preparations 
by use of SDS-PAGE.  The muscle homogenate was prepared by 
disrupting muscle tissue in PBS with a homogenizer (Tissumizer; 
Tekmar, Cincinnati, OH), and the crude and purified nAChRs were 
prepared as mentioned above. All samples received an equal volume 
of 2 x  SDS-gel loading buffer (100 mM Tris-HC1,  pH 6.8,  200 
mM dithiothreitol, 4% SDS, electrophoresis grade, 0.2% bromo- 
phenol blue; 20% glycerol) and were boiled for 10 min. For homo- 
genates, the samples were centrifuged at 14,000 rpm for 10 min, 
and the supernatants were transferred to fresh tubes. To perform 
gel electrophoresis,  a 30-#g aliquot of protein muscle homogenates 
or an 8-/~1 aliquot of crude cell extracts (14 nM/#l)  was loaded 
onto 1.5-mm-thick Tris-glycine 10% polyacrylamide slab gels (Tris- 
glycine electrophoresis buffer: 25 mM Tris base, 250 mM glycine, 
pH 8.3, 0.1% SDS). After SDS-PAGE (16), proteins were electro- 
transferred for 1.5-2 h to membranes (Immobilon; Millipore, Bed- 
ford,  MA)  (transfer buffer:  39  mM glycine,  48  mM "Iris base, 
0.037% SDS, 20% methanol). The membranes were subsequently 
probed with either purified IgG from the sera of e-transgenic mice 
(1:100), sera from patients with MG, sera from patients with non- 
myasthenic disorders,  or the rabbit anti-87-kD postsynaptic mem- 
brane protein polypeptide antibodies of #625  and #638  (1:2,000; 
gifts from Dr. R. L. Huganir, Howard Hughes Medical Institute, 
The Johns Hopkins University School of Medicine, Baltimore, MD). 
After being probed with IgG or sera, the bound antibodies were 
detected with peroxidase-conjugated  goat anti-mouse IgG (1:5,000; 
Boehringer Mannheim Corp., Indianapolis, IN), goat anti-human 
Igs (1:1,000; Sigma Chemical Co., St. Louis, MO), or goat anti- 
rabbit IgG (1:2,000;  Tago, Inc., Burlingame, CA). Finally, peroxi- 
dases on the membranes were visualized with enhanced chemolumi- 
nescence  (Amersham Life Science,  Amersham, UK). 
Immunoprecipitations.  To reveal the antigenic components reac- 
tive to transgenic mouse IgG, we performed immunoprecipitation 
using IgG from BALB/c transgenic mice, MG patients, and anti- 
87-kD-postsynaptic membrane protein polypeptide antibodies #625 
and #638.  The crude cell extracts were isolated from both mouse 
BC3H-1  and  human  TE671  muscle  cell  lines  (17) that  were 
precleared with protein A-Sepharose and protein G-Sepharose 4B 
Fast Flow beads (Sigma Chemical Co.). To form immunocomplex, 
the IgG preparations (100 #g for mouse IgG, 150 #g for MG pa- 
tients, and 1 #g of anti-87-kD-postsynaptic membrane protein poly- 
peptide antibodies #625 and #638) were added separately to 25/xl 
each ofprecleared nAChRs. After 1-h incubation at 4~  the mix- 
tures were reacted with excessive protein A and protein G-Sepharose 
beads.  The antigen-antibody complexes bound to the beads were 
recovered  by sedimentation by microfuge and washed with Tris 
buffer (0.1  M  Tris-HC1,  pH 7.4, 0.15  M  NaC1,  0.01  M  EDTA, 
2% Triton X-100),  repelleted, resuspended in 30 #1 of I  x  SDS 
loading buffer, heated in boiling water for 5 min, and pelleted in 
a microfuge. The proteins in both Sepharose bead-bound pellets 
and supernatants  were analyzed by SDS-PAGE. 
Histological and Immunocytochemical Analysis.  Tissues were fixed 
in Bouin's fixative and processed for paraffin embedding. Sections 
were stained with hematoxylin and eosin (H & E) for histological 
examination and in situ hybridization  experiments.  Immunolabelings 
were performed on unfixed frozen sections. The entire labeling pro- 
cedure was carried out at room temperature. All washes and re- 
agents were in PBS. The nonspecific binding sites were blocked 
in  10%  normal goat serum for 30 rain.  All antibodies were in- 
cubated 30 min and washed three times for 3 min each between 
the two steps.  The primary antibodies were rat anti-mouse CD4 
(PharMingen,  San  Diego,  CA)  and  rat  anti-mouse  Mac-1 
(Boehringer Mannheim Corp.). The secondary antibody was bi- 
otinylated rabbit anti-rat IgG, mouse adsorbed (Vector Labs, Inc., 
Burlingame, CA). Sections  were incubated with an avidin-biotin 
peroxidase complex (ABC kit; Vector Labs,  Inc.) and visualized 
with  diaminobenzidine.  Sections  were  counterstained  with 
Papanicolaou  stain  "EA-65"  or  hematoxylin,  dehydrated,  and 
mounted.  For double-immunofluorescence staining,  the sequen- 
tial staining technique was used.  The nAChRs were stained with 
rhodamine-conjugated ot-bungarotoxin  (otBTX) (Molecular Probes, 
Inc., Eugene, OR) overnight at 4~  The next day, they were con- 
tinually stained with fluorescein-conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) over- 
night  at 4~  All rinses  and reagents were in PBS. 
Electron Microscopy.  For electron microscopy (EM) observations, 
mice were perfused with warmed 2.5% glutaraldehyde.  Muscle was 
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dehydrated in graded ethanol, and embedded in araldyte. 0.5 to 
1.0-#m sections were cut and stained with uranyl acetate and lead 
citrate before viewing with an electron microscope (model 101; 
Siemens, Karlsruhe, Germany) operating at 80 kV. 
Electromyograms.  Mice  were anesthetized with chloral hydrate 
(100 mg/kg) and placed on a heating pad to allow maintenance 
of body temperature at 38~  by use of a heating lamp, tempera- 
ture regulator, and thermistor probe. A stimulating needle elec- 
trode was placed at the Achilles  tendon, and recording needle elec- 
trodes were inserted between the second and third and third and 
fourth digits of the left hind paw. A single supramaximal  stimulus 
(4-6 V, 0.05 ms) was applied adjacent to the peroneal nerve, and 
the resulting electromyogram  was recorded on an analogue storage 
oscilloscope. This was followed by a 1-s train of stimuli (the "ini- 
tial" stimulus; 4-6 V, 0.05 ms, 5 Hz), after which the amplitude 
of each of the five electromyogram (EMG) recordings was mea- 
sured from the screen and the difference  between the amplitude 
of the first and fifth EMG recordings calculated  as the percentage 
change. The system was then provoked by Faradization (4-6 V, 
0.05 millisecond, 50 Hz) for 5 s before application of another 1-s 
train of stimuli (the "provoked" stimulus; 4-6 V, 0.05 millisecond 
5 Hz). A decline of 1>10% in the amplitude between the first and 
fifth EMG recordings of either the initial or provoked stimuli was 
considered  evidence  of neuromuscular  dysfunction (18). All animals 
were coded, and the investigator was unaware of the identity of 
individual mice. 
Results 
Derivation of e-IFN-9~-transgenic  Mice.  To produce trans- 
genic mice expressing  IFN-y in the postsynaptic membrane 
of the neuromuscular  junction, we constructed a recombinant 
DNA plasmid that fused the regulatory sequences of the mu- 
rine nAChR e gene (13) to the coding sequences of the rou- 
tine IFN-y gene (Fig.  1). We chose to use the e subunit of 
the nAChtL because it is the last subunit transcribed during 
ontogeny, starting I d after birth (19). Expression of the IFN-3' 
gene from the e subunit promoter would not, therefore, be 
expected to interfere with the development of  neuromuscular 
junctions in embryos. Of 36 mice born, 10 proved to be trans- 
genic when analyzed by Southern blot hybridization. Trans- 
genic lines were maintained by breeding with BALB/c mice. 
Four transgenic lines were characterized extensively. Animals 
in one of these four lines weighed less than normal but had 
no apparent impairment of mobility at 5 mo of age. How- 
ever, after the sixth month (late onset), muscular weakness 
became visible.  The remaining three lines had similarly re- 
duced body weights but showed locomotor impairment by 
6 wk of age, indicating the early onset of muscular weak- 
ness. In situ hybridization demonstrated the presence of  IFN-7 
RNA in individual dispersed cells within the muscles of trans- 
genic mice. The observed expression  pattern was consistent 
with perijunctional localization of the lymphokine in mice 
from all transgenic lines (Fig.  2). 
Characterization of Appearance and Behavior in e-IFN-~,- 
transgenic Mice.  At birth, the transgenic mice appeared  in- 
distinguishable from their nontransgenic littermates. How- 
ever, after weaning, their weight gain slowed, resulting in 
an ",,25% lower weight for 2-mo-old early-onset transgenic 
mice compared with their nontransgenic littermates. In late- 
onset mice, the weight differences were not as noticeable at 
this stage. The mature transgenic animals then lost 5-10% 
of thdr body weight each month during the observation period 
of 7 mo. Their fur was ruffled, and their distinctive posture 
featured a humped back and drooping head and tail, indi- 
cating muscle weakness.  Further evidence of muscular dys- 
function was their slowed motion, difficulty  in climbing cage 
sides, and long periods of inactivity. Enforced exercise accen- 
tuated their motor impairments. Similar motor dysfunction 
was reported for EAMG induced by the injection of nAChR 
(1,  20-25). 
Anticholinesterase Treatment.  Administration of the anti- 
cholinesterase drug neostigmine temporarily eliminated signs 
of muscle weakness,  as is the case in MG. Within 15 min 
after the transgenic mice were given neostigmine (0.015 mg/kg 
body weight intraperitoneally), they began to traverse  the 
cage actively and groom themselves. This restoration of motor 
activity by neostigmine suggests that an increase in the con- 
centration of acetylcholine, as a result of acetylcholinesterase 
inhibition, augmented the efficiency of neurotransmission. 
Thus, this muscular weakness seems to be a defect of neuro- 
transmission rather  than the contractile properties  of the 
muscle cells. 
x  "#  xx  ~"  ,, 
T  I  I  I 
~-promoter  IF N-V gene 
Figure  1.  Structure of recombinant  ~-IFN-y gene.  The gene  encoding 
IFN-3" was inserted  into the BamH/restriction  site of the 3.5-Kb e gene 
fragment  containing  the promoter  region  (13). An 8.8-kb Xhol/Spel  frag- 
ment containing  the e promoter, the IFN-"/gene, and a terminator  se- 
quence were excised  and purified  for oocyte  injection  as described  previ- 
ously (14). 
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Figure  2.  In situ hybridization  confirming  that IFN-y was expressed 
in neuromuscular  junctions of e-IFN-~'-transgenic  mice. Skeletal  muscles 
from 4-mo-old e-IFN-3,-transgenic  mouse, x160. Electrophysiological  Investigation.  To determine whether the 
morphological changes were associated with functional dis- 
turbances, electrophysiologic testing was performed by use 
of a modification of the procedure described by Pachner and 
Kantor (18). None of nine control nontransgenic mice ex- 
hibited a change in EMG amplitude of >110% during tetanic 
(5 Hz) stimulation, either before or after provocation (Fig. 
3 A). No spontaneous EMG activity was noted in any trans- 
genic mouse, and normal biphasic EMGs were recorded after 
stimulation. Of the early-onset transgenic mice, four out 
of five exhibited  decreases  of  i>10%  in  EMG  amplitude 
during the initial stimulation and also after provocation (Fig. 
3 B). Decreases  of I>10% were also noted in three out of 
six  6-mo-old late-onset transgenic mice during the initial 
stimulation and in five out of six after provocation (Fig. 3 
C). Neostigmine treatment attenuated the decline in EMG 
amplitude after provocation in a late-onset transgenic mouse 
that had previously shown a marked decline (Fig. 3 D). The 
mean changes in EMG amplitude during tetanic stimulation 
for each group before and after provocation are shown in Fig. 
3 E. These decreases in electrophysiologic  test scores indicate 
a disturbance in  neuromuscular transmission that  dosely 
resembles that noted in MG patients (26) and EAMG sub- 
jects (18). 
Histolmthology  of  Muscle in E-IFN-y-transgenic  Mice  By light 
microscopy, H & E-stained sections of muscles showed infiltra- 
tion by lymphocytes, polymorphonudear, and mononuclear 
cells (Fig. 4 A). Individual myofibrils  showed degenerative 
changes, including the appearance of target fibers. Leukocyte 
cell subtypes were identified as MHC class II-expressing mac- 
rophages and occasional  CD4 + T  cells (Fig.  4, B and C). 
Both CD4 + T cells and macrophages are present in human 
MG and have been implicated in the generation of autoim- 
mune responses to nAChR (27). In addition, numerous  plasma 
cells were identified by anti-IgG antibody in the adjacent lymph 
node. In other organs, including the thymus, no apparent 
abnormality was found. 
UltrastructuralAnalysis.  EM of skeletal muscles from both 
early- and late-onset transgenic mice revealed ablation of  junc- 
tional folds of the sarcolemma (Fig. 5), suggesting  a reduction 
in the number of nAChK (28, 29). Strikingly, macrophages 
were consistently present adjacent to the morphologically al- 
Figure 3.  EMGs from control (tt) and early-onset (B) 
e-IFN-',/-transgenic  mice  after  tetanic  stimulation (30). 
A late-onset transgenic animal with a marked decline in 
EMG amplitude (C) was allowed to recover  from anesthesia, 
and tetanic stimulation was repeated 80 min after treatment 
with neostigmine (0.015 mg/kg, i.p.) (D). The mean per- 
centage of decline during the initial and provoked stimuli 
was calculated for all three groups (E), and statistical com- 
parisons were made by one-way analysis  of  variance  followed 
by the Neuman-Keuls test when the F test gave p <0.05. 
Data  are mean  _+  SE. 
550  Myasthenia Gravis-like Syndrome in IFN-3" Transgenics Figure  4.  Cellular  infiltrates  on  skeletal muscles 
from  4-mo-old  e-IFN-7  mice.  (.4)  Limb  muscle 
showing monocytic infiltration  (H  & E  stain).  (B) 
CD4 +  T  calls  (center)  and  atrophic  muscle  fibers 
(arrows) shown  by immunoperoxidase  labeling.  (C) 
Mac-1 * cells. For B and C, cryostat sections were la- 
beled with rat anti-CD4 or rat anti-Mac 1 antibodies. 
The secondary antibody was biotinylated rabbit anti-rat 
lgG. Sections were incubated in avidin-biotin peroxi- 
dase complex and visualized with diaminobenzidine. 
Sections were counterstained  with Papanicolaou stain 
"EA-65" or hematoxylin,  dehydrated,  and mounted. 
x 160. 
551  Gu et al. Figure 5.  Comparison  of motor end plates in the inter- 
costal muscles of control (A) and e-IFN-3,-transgenic  (B) 
mice (￿  and  ￿  respectively). The control 
mouse has a myelinated  axon (ax) terminating at the neu- 
romuscular  junction with its complex  junctional infoldings 
(arrows). The e-IFN-q,-transgenic mouse lacks these  junc- 
tional infoldings  (arrows) and displays  axonal  (ax) shrinkage 
as well as retraction of the Schwann ceUs (sc) from the ter- 
minal axon. 
tered neuromuscular junctions (Fig. 6). Simplification of the 
postsynaptic membrane occurs commonly in the neuromus- 
cular  junctions of MG patients (30-32) or animals with chronic 
EAMG (28), but phagocytic invasion does not. In fact, phago- 
cytic invasion of neuromuscular junctions  is  usually noted 
only in acute or passively transferred EAMG. Furthermore, 
in the adjacent lymph nodes, the appearance of plasma cells 
containing ultrastructural characteristics of IgG hypersecre- 
552  Myasthenia  Gravis-like Syndrome in IFN-'y Transgenics Figure  6.  Intercostal  muscle  from an E-IFN-3'-transgenic 
mouse. Mononuclear cells (m) were regularly noted adja- 
cent to abnormal terminal regions of axons (ax). x 12,300. 
tion (Russell bodies) indicated the activation of the humoral 
immune  system. 
Autoantibody Deposition.  Immunohistochemical  staining 
experiments were performed with FITC-conjugated antibody 
against mouse IgG on cryostat sections of muscle from trans- 
genic and control mice. Intense staining by mouse IgG was 
visible as deposits believed to be at the motor end plates of 
skeletal muscles (Fig.  7 B). In 2-mo-old mice of the early- 
onset group, staining was restricted to a few weakly staining 
motor  end plate structures.  However, by 4  mo  of age,  in- 
tense staining of a large number of motor end plates was ob- 
served. This progression from a few weakly stained end plates 
to many strongly stained ones during  the interval between 
2 and 4 mo of age correlated with  the time period during 
which clinical symptoms arose. The late-onset mice showed 
a similar staining pattern only after they reached I>6 mo of 
age.  The localization  of IgG deposition  to the motor  end 
plate region was confirmed by double-labeling experiments 
using rhodamine-conjugated  olBTX to probe for nAChRs. 
Indeed, the fluorescein label colocalized with the otBTX la- 
beled (Fig.  7,  A  and B).  Our  observations of the  otBTX- 
labeled muscle tissues revealed that most synaptic clefts from 
transgenic  mice appeared as slender elongated  structures,  a 
shape that  was quite distinct  from  those of nontransgenic 
mice. Furthermore, the few fairly normal appearing synaptic 
clefts of these mice were not double labeled with the fluorescei- 
nated antibody.  The  IgG deposits in  synaptic clefts of the 
transgenic mice accumulated in circular loci, some of which 
also stained with otBTX. Such round loci were never detected 
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in tissues from nontransgenic  mice tested with  the olBTX 
label. Studies in which these areas were double stained with 
hematoxylin indicated that the round loci did not correspond 
to  nuclei,  and  possibly  represent  capping  structures  of 
membrane-bound antibody. The purified IgG from e-tram- 
genic mouse sera also positively stained the motor end plates 
of BALB/c muscles (Fig.  7, C  and D). No staining was ob- 
served in BALB/c muscle when purified IgG from BALB/c 
sera was used (data not shown). These results strongly sug- 
gest that  the IFN-3' expressed in  the neuromuscular junc- 
tion induced a humoral autoimmune response toward com- 
ponents  in  the  motor  end plates. 
Target Antigen Detection.  A  large percentage of MG pa- 
tients exhibit humoral autoimmunity to motor end plate con- 
stituents, most commonly directed at the nAChR. To inves- 
tigate  whether  our  IFN-3,-transgenic  mice  had  a  similar 
immune  response,  we looked directly for anti-nAChR  au- 
toantibodies by use of labeled c~BTX and performed Western 
blots on purified IgG from transgenic and control mice. As 
our source of antigen, we used the mouse cell line BC3H-1, 
which expresses muscle nAChRs and is presumably derived 
from a motor end plate (33). We failed to detect any autoan- 
tibodies to nAChRs in the serum from transgenic mice (data 
not shown).  Interestingly,  however, we were able to consis- 
tently detect an 87-kD band on Western blots of BC3H-1 
extracts that appeared with serum from all 12 transgenic mice 
analyzed. This band did not appear when brain extracts were 
used as antigen  (data not  shown). 
Since a category of MG patients are "seronegative" having Figure 7.  Detection of IgG deposition in transgenic motor end plates and the binding of transgenic IgG to BALB/c  motor end plates (mouse age: 
4 mo). The motor end plate was first identified by rhodamine-conjugated  otBTX. (A) Muscle from transgenic mouse; (c) muscle from BALB/c mouse. 
(/3) The presence of IgG in the same motor end plate of a transgenic mouse was visualized  by FITC-conjugated goat anti-mouse IgG. (/9) BALB/c 
muscle was incubated first with transgenic IgG followed by FITC-conjugated goat anti-mouse IgG; the motor end plate was also labeled, indicating 
that transgenic mice contained antibodies to some component(s) of motor end plates. When IgG from nontransgenic control mice was used to stain 
BALB/c muscles, no staining was observed (not shown). A, B,  x450; C, D,  xl,000. 
no measurable anti-nAChR antibodies, we wondered whether 
the 87-kD protein found in the transgenic mice represented 
an additional target antigen that was shared with seronega- 
tive MG patients. We therefore obtained sera from seronega- 
tive MG patients  and performed similar Western blot anal- 
Figure 8.  Reactivity of transgenic mice and human MG patients to 
components in the BC3H-1 cell line extract. Western blotting  analysis 
revealed  that antibodies  from individual  mice and MG patients consistently 
recognized an 87-kD protein in the extracts. (Lanes 1-3) IgG from trans- 
genic mice. (Lanes  4-7) Sera  from MG-seronegative  patients. (Lanes  8-10) 
Sera from MG-seropositive  patients. (Lanes  11-13) sera  from patients with 
non-MG autoimmune disorders. Note the absence of a 87-kD band. 
ysis.  Strikingly, these samples contained an 87-kD protein, 
which was labeled by sera from 15/15 seronegative MG pa- 
tients.  The protein recognized by mouse purified IgG and 
human sera appeared identical in size. We also detected im- 
munoreactivity to the 87-kD band in 8/14 seropositive MG 
patients. Importantly, the 87-kD protein was not recognized 
by purified IgG from either BALB/c mice or sera from 7/8 
of nonmyasthenic patients (Fig. 8 and Table 1). To determine 
whether the 87-kD protein was similar in mice and humans, 
we performed cross-immunoprecipitation  experiments.  We 
immunoprecipitated extracts from the murine muscle cell line 
BCH3-1  and  human  tumor cell line TE671  using purified 
transgenic mouse IgG or human MG IgG, and Western blots 
were performed on  the  immunoprecipitated  material  with 
sera from the other species. We were able to detect the human 
immunoprecipitation product with the mouse IgG, and vice 
versa (Fig.  9). 
An 87-kD postsynaptic membrane protein has been previ- 
ously reported in vertebrate muscle (34,  35).  To determine 
whether this 87-kD protein was the one recognized by IgG 
from  transgenic  mice  (e-IgG),  we  obtained  anti-87-kD- 
postsynaptic membrane protein antibodies (anti-87-kD-PSMP- 
554  Myasthenia  Gravis-likeSyndrome in IFN-3' Transgenics Table  1.  Results  of Western Blot Analysis in Mice and 
Seronegative and Seropositive MG Patients 
Source of IgG or Sera 
Positive 87-kD protein 
%  Positive/Total 
e-IFN-3,-transgenic  mice 
BALB/c mice 
Seronegative MG patients 
Seropositive MG patients 
Nonmyasthenic  disorder 
100  (12/12) 
0  (0/6) 
100  (15/15) 
57.2  (8/14) 
14  (1/8) 
Crude cell extract was prepared from the BC3H-1 cell line. There was 
an 87-kD protein labeled  with purified IgG from 12 transgenic mice or 
sera from 15 seronegative and 8 seropositive  MG patients. This 87-kD 
protein stained negatively with purified IgG from either BALB/c mice 
or sera from most of the nonmyasthenic autoimmune disorder patients. 
One patient out of eight showed positive staining. 
Ab,  a  generous  gift  from  R.  Huganir)  and  prepared  im- 
munoprecipitates  from our crude extracts.  The antigen  su- 
pernatants  were collected and allowed to reprecipitate with 
either  anti-87-kD-PSMP-Ab  or e-IgG.  SDS-PAGE showed 
that anti-87-kD-PSMP-Ab and e-IgG each quantitatively re- 
moved its own respective protein, but failed to recognize the 
other (data not shown). These results demonstrate that there 
was no cross-reactivity between anti-87-kD-PSMP-Ab  and 
e-IgG and strongly suggest that our crude extract 87-kD pro- 
tein is not the same as postsynaptic membrane  87-kD pro- 
tein in the motor  end plates. 
Discussion 
While the perturbations used to produce transgenic mice 
cannot,  by definition,  copy naturally occurring  conditions, 
we have demonstrated some striking similarities  between the 
e-IFN-3,-transgenic mice and aspects of human MG. These 
include overt muscular weakness, simplification of the post- 
synaptic membrane, progressively declining EMG responses 
to stimulation, restoration of motor activity by anticholines- 
terase drugs,  and infiltration  of muscles by cells  of the im- 
mune system. Additionally, both human MG and our trans- 
genic mice demonstrate deposition of antibody at motor end 
Figure 9.  The proteins immunoprecipitated from BCH3-1 extracts  by 
use of  transgenic mouse  IgG or MG patient IgG. (Lane  1) Control BALB/c 
IgG. (Lanes  2-4) Probed with individual transgenic mouse IgG. (Lanes 
5-11) Probed with individual human MG patient IgG. 
plates, which in our mice occurs during the preclinical period. 
Lastly, we have demonstrated the presence of antibody directed 
against  an 87-kD protein in crude mouse BC3H-1 and human 
TE671  extracts  that  is  shared by transgenic  mice,  human 
seronegative MG patients,  and the majority of seropositive 
MG patient  sera we studied. 
The pathogenic significance of immunological  sensitiza- 
tion to the 87-kD antigen remains to be determined. Prelim- 
inary immunofluorescence studies using sera from transgenic 
mice on cultured BC3H-1 cells demonstrated cell surface lo- 
calization of the 87-kD antigen. It is possible that these anti- 
bodies may bind to epitopes of a protein closely associated 
with the nAChK and are capable of modulating its function 
indirectly. The possible physical association between the 87- 
kD antigen  and the nAChR is supported by the fact that 
we could detect the 87-kD band with e-IFN-3, sera on Western 
blots of partially purified nAChK.  This suggests, but does 
not prove, that  the 87-kD protein could coprecipitate with 
the nAChR.  Previous studies have shown that  Ig obtained 
from "seronegative" patients, when injected into experimental 
animals,  caused loss of nAChRs  and  decreased amplitudes 
of motor end plate potentials,  thus providing  evidence for 
the presence of antibody directed against some postsynaptic 
component of the neuromuscular junction (36, 37). Our data 
on humans and mice suggest that this antigen could be the 
87-kD band we have identified.  Further experimentation  is 
warranted  to address  this point. 
The histological lesions in this model consisted of inflam- 
matory cell infiltrates that could result from the response to 
viral infection or autoimmune disease.  These inflammatory 
infiltrates,  composed  mainly  of macrophages,  were  quite 
different in cellular composition from the more diverse pan- 
creatic infiltrates  (including CD8 + T  and B cells) previously 
observed in transgenic  mice expressing IFN-3' in the islets 
of Langerhans  (38). Interestingly,  pancreatic expression of quite 
disparate signals such as the Th2 cytokine IL-10 are capable 
of recruiting  infiltrates  that  are  surprisingly  similar in cel- 
lular composition to the pancreatic infiltrates observed with 
IFN-3~ expression (39). Thus, identical signals  (IFN-3,) lead 
to  pronounced  differences  in  inflammatory  responses  in 
different  tissues, while disparate  signals lead to similar recruit- 
ment patterns  in the same tissue.  This might  be mediated 
at the level of the tissue endothelium, which has been demon- 
strated in vivo to respond to localized expression of IFN-'y (40). 
The  expression of IFN-y leads  to pathogenic  responses 
mediated by distinct arms of the immune system in each tissue. 
In the neuromuscular disease of our transgenic mice, the au- 
toantibody deposits at the motor end plates imply autoim- 
munity in the humoral compartment. However, no CD8 cells 
could be identified within the transgenic musdes, implying 
the lack of participation of a cell-mediated response. This is 
quite distinct from transgenic mice expressing IFN-~/in the 
pancreas,  where no humoral response could be identified by 
either islet cell antibodies or by studying the humoral response 
to specific islet constituents (41).  In contrast, pancreatic ex- 
pression of IFN-3~ leads to infiltration by CD8 cells and the 
development of cell-mediated immunity to islet constituents 
555  Gu et al. (41,  42).  This Thl lymphokine, which is associated  with 
stimulating such cell-mediated responses, in the milieu of the 
neuromuscular  junction induces humoral autoimmunity. This 
leads us to speculate that tissue-specific tropic factors could 
contribute to a localized immune response,  enhancing, for 
example, a humoral rather than a ceU-mediated response (such 
as is seen in human MG). Such factors might normally par- 
ticipate in a host's defense of a specific region. Indeed, access 
to "sterically" sequestered  areas/antigens, such as the neu- 
romuscular  junction, would necessitate emphasis on humoral 
immunity over a cell-mediated response.  This effect could 
account for the disparity in the primarily humoral response 
to glutamic acid decarboxylase antigen in the brain, which 
leads to the neurological disease stiff-man syndrome, whereas 
a cell-mediated response to the same tissue-specific  antigen 
in pancreatic islets  is  associated  with the development of 
insulin-dependent diabetes  mellitus (43,  44). 
The IFN-7-transgenic model is useful because of the in- 
heritable nature of trangenes, providing a mouse strain for 
prolonged experiments. In contrast,  some EAMG animals 
exhibit a self-limiting disease that subsides  several months 
after primary immunization. Several differences exist between 
our transgenic model and human MG. As in EAMG (45), 
our transgenic mice had no evidence  of hyperplasia or thy- 
moma in any of seven thymuses examined, whereas '~50% 
of MG patients develop hyperplasia,  and "~10% also develop 
benign or malignant tumors. Additionally, although we rou- 
tinely saw macrophages in the vicinity of disrupted neuromus- 
cular  junctions, and the postsynaptic membrane displayed the 
simplification characteristic  of  both EAMG and human MG, 
the overall amount of inflammatory cell recruitment in our 
transgenic model is much higher than that reported for MG. 
This is probably due to more avid recruitment as a secondary 
phenomenon to endothelial cell activation, which is regu- 
lated by the constitutive expression  of IFN-3,. 
In transgenic mice, we have demonstrated a humoral re- 
sponse to motor end plate components that results from local- 
ized lymphokine expression. Our results suggest that human 
MG could be initiated by immune defense molecules expressed 
in response to an environmental insult such as infection. Sen- 
sitization to the nAChR or other motor end plate compo- 
nents might then occur as a secondary event.  Inflammation 
and autoantibodies in the neuromuscular junction can sub- 
stantially impair neuromuscular transmission and cause clin- 
icaUy apparent  muscular  weakness.  Although  the  entire 
pathway from cytokine to disease is not totally dear, our work 
directly links such inflammatory mediators to MG. 
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